Mind Medicine (MindMed) Q2 2025 Earnings Report

Mind Medicine (MindMed) EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.37
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Mind Medicine (MindMed) Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Mind Medicine (MindMed) Announcement Details

• Quarter: Q2 2025
• Date: 8/12/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 12, 2025
• Conference Call Time: 8:00AM ET

Mind Medicine (MindMed) (NASDAQ:MNMD) is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for mental health disorders and addiction through the controlled use of psychedelic-inspired compounds. Established in 2019 and headquartered in New York, MindMed leverages advances in neuroscience to explore molecules such as LSD analogues, ibogaine derivatives and other psychoactive substances. The company’s mission is to address unmet needs in conditions including anxiety, depression, post-traumatic stress disorder and substance use disorders by harnessing the therapeutic potential of these compounds under rigorous clinical protocols.

MindMed’s pipeline includes a range of investigational therapies designed to offer single- or short-course dosing regimens with the goal of achieving sustained clinical benefit. Key programs involve an ibogaine-derived compound targeting opioid withdrawal and dependence, as well as next-generation analogues of lysergic acid diethylamide (LSD) being evaluated for anxiety and addiction treatment. Studies are conducted in compliance with regulatory guidelines, with research sites spanning North America and Europe to advance multiple Phase 2 trials.

The company collaborates with leading academic institutions and research organizations to deepen scientific understanding of psychedelic-assisted therapy. Partnerships with entities such as Imperial College London and Johns Hopkins University support neuroimaging, safety assessments and behavioral studies. MindMed also maintains strategic alliances with contract manufacturing organizations to ensure high-quality production of its proprietary drug candidates under Good Manufacturing Practice standards.

Under the leadership of Chief Executive Officer JR Rahn, MindMed has grown its global footprint with offices in Zurich, London and Vancouver, in addition to its New York headquarters. The executive team combines experience in biotech development, regulatory affairs and psychiatry research, positioning the company to navigate the evolving landscape of psychedelic-based therapeutics and bring innovative mental health treatments to market.